Corticosteroid Treatment for Prevention of Prematurity Complications

Basit Öğe Kaydı
dc.contributor.authorÇelik, Çetin
dc.contributor.authorAcar, A.
dc.contributor.authorÇiçek, N.
dc.contributor.authorKoç, H.
dc.contributor.authorAk, D.
dc.contributor.authorAkyürek, Cemalettin
dc.date.accessioned2020-03-26T16:44:59Z
dc.date.available2020-03-26T16:44:59Z
dc.date.issued2002
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective: To investigate of efficiency to corticosteroid treatment for prevention of respiratory distress syndrome and other prematurity complications. Materials and Methods: One thousand and six babies born at 26-36th gestational age were investigated for following parameters; the development of respiratory distress syndrome, necessity of surfactant therapy, mean duration of daily ventillatory support, rates of Grade III or IV intraventricular hemorrhage, and periventricular leukomalacia, necrotizing enterocolitis, proven neonatal sepsis and neonatal death. Antenatal steroids were administered in the form of two 12-mg intramuscular doses of betamethasone 12 h apart as a total 24 mg in the 24 h and repeat courses of two 12 mg of betamethasone every 7 days after the first dose of the last course if undelivered. Babies were divided into 4 groups based on betamethasone treatment: The first group or control group didn't received treatment; the second group received treatment and delivered within 12 h after first injection; the third group delivered 12-24 h after first injection; and fourth group delivered at least 24 h after first injection. The patients ongoing pregnancy at least 1 week were divided into two groups as a single dose and multiple courses in once a week. Results: Significant difference for development of respiratory distress syndrome between fourth group and others was found (p=0.029). There were significant difference for respiratory distress syndrome rate in hypertansive and premature rupture of membranes groups between fourth group and control group (p=0.002, p=0.041). There weren't significant difference for RDS between repeat doses and single dose groups (p>0.05). Conclusion: Single dose corticosteroid is an effective treatment for the development of RDS and the prevention of other prematurity complications.en_US
dc.identifier.citationÇelik, Ç., Acar, A., Çiçek, N., Koç, H., Ak, D., Akyürek, C., (2002). Corticosteroid Treatment for Prevention of Prematurity Complications. Archives of Gynecology and Obstetrics, (267), 90-94. Doi: 10.1007/s00404-001-0271-6
dc.identifier.doi10.1007/s00404-001-0271-6en_US
dc.identifier.endpage94en_US
dc.identifier.issn0932-0067en_US
dc.identifier.pmid12439554en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage90en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s00404-001-0271-6
dc.identifier.urihttps://hdl.handle.net/20.500.12395/18143
dc.identifier.volume267en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÇelik, Çelik
dc.institutionauthorAcar, A.
dc.institutionauthorÇiçek, N.
dc.institutionauthorKoç, H.
dc.institutionauthorAk, D.
dc.institutionauthorAkyürek, C.
dc.language.isoenen_US
dc.relation.ispartofArchives of Gynecology and Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectCorticosteroid treatmenten_US
dc.subjectPrematurityen_US
dc.titleCorticosteroid Treatment for Prevention of Prematurity Complicationsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
makale29.pdf
Boyut:
134.56 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Kadın Hastalıkları ve Doğum/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu